MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

89bio, Inc. - Common Stock (NQ:ETNB)

14.71 +0.01 (+0.03%)
Streaming Delayed Price Updated: 2:26 PM EDT, Sep 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about 89bio, Inc. - Common Stock

< Previous 1 2 3 4 Next >
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PGRE, BERY, COMP, ETNB on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PGRE, ETNB, STAA on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
89BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 89bio, Inc. - ETNB
From Kahn Swick & Foti, LLC
Via Business Wire
ETNB Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of 89bio, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Shareholder Alert: The Ademi Firm Investigates Whether 89bio, Inc. is Obtaining a Fair Price for its Public Shareholders
From Ademi & Fruchter LLP
Via Business Wire
89bio, Inc. Announces Agreement to be Acquired by Roche
From 89bio, Inc.
Via GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
89bio to Participate in Upcoming Investor Conferences
From 89bio, Inc.
Via GlobeNewswire
89bio Reports Second Quarter 2025 Financial Results and Corporate Updates
From 89bio, Inc.
Via GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
89bio to Participate in Goldman Sachs 46th Annual Global Healthcare Conference
From 89bio, Inc.
Via GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
89bio to Participate in Upcoming Investor Conferences
From 89bio, Inc.
Via GlobeNewswire
89bio Reports First Quarter 2025 Financial Results and Corporate Updates
From 89bio, Inc.
Via GlobeNewswire
89bio to Participate in the Leerink Partners Global Healthcare Conference
From 89bio, Inc.
Via GlobeNewswire
89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
From 89bio, Inc.
Via GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
89bio Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From 89bio, Inc.
Via GlobeNewswire
89bio, Inc. Announces Pricing of $250.0 Million Public Offering of Common Stock and Pre-Funded Warrants
From 89bio, Inc.
Via GlobeNewswire
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
From 89bio, Inc.
Via GlobeNewswire
89bio Provides Business Update and Outlook for 2025
From 89bio, Inc.
Via GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
89bio to Participate in the 7th Annual Evercore HealthCONx Conference
From 89bio, Inc.
Via GlobeNewswire
89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024
New post-hoc analyses reinforce pegozafermin’s potential anti-fibrotic effects and the potential utility of non-invasive tests which correlate to histological endpoints 
From 89bio, Inc.
Via GlobeNewswire
89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants
From 89bio, Inc.
Via GlobeNewswire
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
From 89bio, Inc.
Via GlobeNewswire
89bio Reports Third Quarter 2024 Financial Results and Corporate Updates
From 89bio, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
TOP
Email a Story